Danaher's AI-driven life-sciences expectations look excessive against its results. After a 44% rise since May on hopes AI would lift life sciences to unprecedented levels, it missed Q3 revenue and guided Q4 growth to just 4-5%. x.com 

Agilent could benefit significantly as AI adoption in drug discovery and life sciences boosts demand for research infrastructure. Strong free cash flow and an improving EPS outlook accompany its massive five-year base; the larger base points to greater upside. x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

ASML's reported inability to make enough machines for the next two years is a buy signal for the whole AI stack. Its stock still sold off despite that shortage. x.com 

Iambic's R&D split and the basket's returns show why data-generating lab work matters more than compute in applied AI biotech. Iambic's S-1 puts about 8 cents of its 2025 R&D dollar into compute, 31 into discovery and the lab, and 28.5 into the clinic. After two months, the basket rose 20.5% versus -0.2% for the S&P 500 and -4.8% for biotech. Data-producing names rose 33.5%, or 16.8% without Moderna's readout day, versus 9% for bioprocess and reagents. The market bought the data. x.com 

Biotech tools stocks such as Charles River and Illumina are in a narrative-driven mania while their fundamentals haven't really moved. Charles River is ripping after reaffirming guidance for negative revenue growth this year. Illumina hasn't grown in five years, yet trades at over 50x earnings and 35x EV/EBITDA, with merely fine margins. Five straight years of easier comparisons are being sold as a coiled spring. x.com  x.com  x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Micron's knockout earnings should soon lift a stock that hasn't moved yet, likely because of end-of-month fund repositioning. It beat on revenue, margins and earnings and projects an even bigger 2027. AI supply-chain assets were weak in September, historically the worst month of the year, while October is historically the best. x.com  x.com 

Amtech Systems is a turnaround bet on a savvy CEO who has repositioned it toward advanced AI packaging. Since Bob Daigle took over in 2023, a move to a largely fabless model has lifted gross margin from -2% to 48%, after seven factories, cyclical markets and an Entrepix write-down drove losses. Its reflow ovens see strong demand for GPU and HBM assembly, and panel-level packaging could add orders. Risks: it is tiny against Heller, Rehm and cheap Chinese rivals, and a shift to hybrid bonding. … Show more

Veeco is an AI pick-and-shovel play ramping from a 2025 trough, because its laser spike annealing tools are tool-of-record for gate-all-around transistors at TSMC, Intel and Samsung. Requalification is costly, so those wins lock in demand as fabs ramp, and its annealing market should grow from ~$600 million to $1 billion-plus. Ion beam deposition, HBM packaging and the Axcelis merger add growth, with FY2026 guidance of $740-800 million revenue. The key risk is China's SAMR blocking the merger. … Show more